f t # e

Over the last few decades, costs of healthcare and prescription drugs have increased at an unprecedented rate. As your representative, I'm deeply concerned about the financial burden this places on Americans and particularly families in western North Carolina. Given the urgency of this issue, I am constantly seeking out bipartisan solutions where both parties can work together to provide relief for families across the country, expanding the supply of prescription drugs and increasing competition in the U.S. market.

I've introduced two bills to address underlying problems in the market that contribute to these soaring prices:

  • H.R.2038 - The State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019. This bill would lower the costs of prescription drugs by allowing insurers to jointly negotiate prices of prescription drugs purchased from drug manufacturers.

  • H.R.2209 - The Fixing Global Freeloading Act. This bill would establish a Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative responsible for conducting trade negotiations and enforcing trade agreements to ensure that the United States’ pharmaceutical innovations are appropriately rewarded.

I've also done bipartisan work on legislation that addresses several important facets that affect the high cost of prescription drugs—resulting in cosponsoring the following legislation:

  • H.R. 965 – Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. CREATES aims to stop brand-drug makers from withholding samples that generic drug makers need to pursue U.S. Food and Drug Administration (FDA) review and approval.

  • H.R.2376 - Prescription Pricing for People Act of 2019. This bill requires the Federal Trade Commission (FTC) to study the role of pharmacy benefit managers in the drug supply chain and make recommendations for how to improve transparency and competition.

  • H.R.2374 - Stop STALLING Act. This bill ends the practice of sham petitions by drugmakers to delay FDA approval of lower-cost generic alternatives.

  • HR 2375 – The Preserve Access to Affordable Generics and Biosimilars Act is halts anticompetitive agreements between generic and brand name manufacturers. Most recently, the FTC found that even an agreement not to market an authorized generic can be considered a form of reverse payment to delay the entry of generic competition.

  • H.R.938 - BLOCKING Act of 2019. Currently, federal law awards 180 days of market exclusivity to a drug manufacturer that’s the first to file a generic drug application with the FDA for a drug that doesn’t yet have a generic form. The 180-day exclusivity clock starts as soon as a manufacturer begins marketing the drug. At that point, all other generic competitors are blocked from coming to market. Some manufacturers have been allowed to “park” their 180-day exclusivity application before actually receiving final approval on it, subsequently blocking competition beyond the permitted 180 days. This bill amends Section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act to close this anti-competitive, regulatory loophole.

f t # e

Stay Connected

Use the form below to sign up for my newsletter and get the latest news and updates directly to your inbox.